Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201562 · ClinicalTrials.gov registry record · Phase 2
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Phase 2 study, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03201562 is a Phase 2 study that has completed, run by LENZ Therapeutics. The registered enrollment target is 58 participants.
The verdict
NCT03201562, a Phase 2 study, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.
Interventions
- DRUG Vehicle
- DRUG Aceclidine+tropicamide combination
- DRUG Aceclidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-04-30 |
| Est. Completion | 2018-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03201562
The ClinicalTrials.gov registry entry for NCT03201562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT03201562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03201562 about?
NCT03201562 is a clinical study titled "A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia". To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.
What is the current status of trial NCT03201562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2017-04-30. Estimated completion is 2018-05-20.
What interventions are being tested in trial NCT03201562?
The interventions under investigation include: Vehicle (DRUG), Aceclidine+tropicamide combination (DRUG), Aceclidine (DRUG).
Who is sponsoring clinical trial NCT03201562?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.